{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:47:55Z","timestamp":1774352875198,"version":"3.50.1"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020247","name":"University of Bisha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.prp.2025.156145","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:11:39Z","timestamp":1753456299000},"page":"156145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Molecular carcinogenesis in Hodgkin lymphoma: Interplay between B lymphocyte mutations and NF-\u03baB pathway dysregulation"],"prefix":"10.1016","volume":"273","author":[{"given":"Mohammed H.","family":"Abu-Alghayth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2025.156145_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.prp.2025.156145_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154627","article-title":"Polyamine catabolism is concentrated in tumor-associated histiocytes in diffuse large B-cell lymphoma and classic Hodgkin lymphoma","volume":"248","author":"Bronson","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156145_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib4","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.3390\/jcm10204665","article-title":"Hodgkin lymphoma: a special microenvironment","volume":"10","author":"Opinto","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.prp.2025.156145_bib5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ajh.26717","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management","volume":"97","author":"Ansell","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.prp.2025.156145_bib6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/jcm10051125","article-title":"Hodgkin lymphoma\u2014Review on pathogenesis, diagnosis, current and future treatment approaches for adult patients","volume":"10","author":"Momotow","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.prp.2025.156145_bib7","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.3390\/cancers14112647","article-title":"An update on the pathology and molecular features of Hodgkin lymphoma","volume":"14","author":"Satou","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib8","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3390\/biomedicines10092153","article-title":"NFkB Pathway and Hodgkin Lymphoma","volume":"10","author":"Jardin","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2025.156145_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","article-title":"NF-\u03baB deregulation in Hodgkin lymphoma","volume":"39","author":"Weniger","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.prp.2025.156145_bib10","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.3390\/ijms21186623","article-title":"Molecular pathogenesis of hodgkin lymphoma: past, present, future","volume":"21","author":"Bienz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156145_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.biopha.2017.08.120","article-title":"IL-1\u03b2-induced NF-\u03baB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1","volume":"95","author":"Hu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2025.156145_bib12","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3390\/cancers13143634","article-title":"Immune microenvironment features and dynamics in Hodgkin Lymphoma","volume":"13","author":"Bertuzzi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib13","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.3390\/cancers15215217","article-title":"Prognostic markers within the tumour microenvironment in classical Hodgkin Lymphoma","volume":"15","author":"Martynchyk","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib14","doi-asserted-by":"crossref","first-page":"1155468","DOI":"10.3389\/fimmu.2023.1155468","article-title":"New molecular targets in Hodgkin and Reed-Sternberg cells","volume":"14","author":"Sadaf","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2025.156145_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1203470","article-title":"Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin\/Reed-Sternberg cells","volume":"13","author":"Cellini","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib16","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ajpath.2023.08.012","article-title":"Evolution of lymphoma diagnosis in the era of personalized medicine: a marriage of pathology and genomics for clinical practice","volume":"193","author":"Jaffe","year":"2023","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.prp.2025.156145_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.molmed.2024.10.004","article-title":"Advances in Hodgkin lymphoma research","volume":"31","author":"K\u00fcppers","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.prp.2025.156145_bib18","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41598-025-86664-x","article-title":"Clinical significance of PCT, CRP, IL-6, NLR, and TyG Index in early diagnosis and severity assessment of acute pancreatitis: a retrospective analysis","volume":"15","author":"Xinyu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2025.156145_bib19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/cancers13040682","article-title":"Genomic landscape of Hodgkin Lymphoma","volume":"13","author":"Brune","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib20","first-page":"523","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma, Blood","volume":"135","author":"Kline","year":"2020","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2025.156145_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40588-019-00120-9","article-title":"Epstein-Barr Virus and the Human Leukocyte antigen complex","volume":"6","author":"Li","year":"2019","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"10.1016\/j.prp.2025.156145_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.gendis.2020.06.005","article-title":"The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases","volume":"8","author":"Zinatizadeh","year":"2021","journal-title":"Genes Dis."},{"key":"10.1016\/j.prp.2025.156145_bib23","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3390\/cancers14051360","article-title":"The Hodgkin lymphoma immune microenvironment: turning bad news into good","volume":"14","author":"Men\u00e9ndez","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-024-03108-6","article-title":"Hodgkin lymphoma and liquid biopsy: a story to be told","volume":"43","author":"Velasco-Suelto","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2025.156145_bib25","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3390\/diagnostics12040963","article-title":"The need for standardization in next-generation sequencing studies for classic Hodgkin lymphoma: a systematic review","volume":"12","author":"Santisteban-Espejo","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.prp.2025.156145_bib26","doi-asserted-by":"crossref","first-page":"1275327","DOI":"10.3389\/fonc.2023.1275327","article-title":"The implication of next-generation sequencing in the diagnosis and clinical management of non-Hodgkin lymphomas","volume":"13","author":"Tomacinschii","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41379-021-00983-8","article-title":"Clonality assessment and detection of clonal diversity in classic Hodgkin lymphoma by next-generation sequencing of immunoglobulin gene rearrangements","volume":"35","author":"van Bladel","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2025.156145_bib28","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17719","article-title":"Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping","volume":"195","author":"Alcoceba","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.prp.2025.156145_bib29","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3390\/cancers13081751","article-title":"Next generation sequencing technology in the clinic and its challenges","volume":"13","author":"Vestergaard","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib30","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood.2022017147","article-title":"Novel insights into Hodgkin lymphoma biology by single-cell analysis","volume":"141","author":"Aoki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156145_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123757","article-title":"The evolving knowledge on T and NK cells in classic Hodgkin lymphoma: insights into novel subsets populating the immune microenvironment","volume":"12","author":"Ferrarini","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1146\/annurev-immunol-110519-071134","article-title":"Insights gained from single-cell analysis of immune cells in the tumor microenvironment","volume":"39","author":"Ren","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.prp.2025.156145_bib33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2105822118","article-title":"Single-cell profiling reveals the importance of CXCL13\/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma","volume":"118","author":"Aoki","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2025.156145_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.149","article-title":"Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes","volume":"8","author":"de Kanter","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.prp.2025.156145_bib35","doi-asserted-by":"crossref","DOI":"10.1158\/2643-3249.LYMPHOMA22-A37","article-title":"Abstract A37: single-cell RNA sequencing reveals that childhood classical Hodgkin Lymphoma resembles normal inflammation except for T cell exhaustion","volume":"3","author":"de Kanter","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.prp.2025.156145_bib36","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.21037\/tcr-23-1146","article-title":"Application and progress of CRISPR\/Cas9 gene editing in B-cell lymphoma: a narrative review","volume":"13","author":"Jin","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.prp.2025.156145_bib37","unstructured":"Pan, Y.; Cengiz, R.; Hashami, Z.S.; de Bruin, W.; Terpstra, M.; Seitz, A.; Koerts, J.; Kooistra, W.; de Jong, D.; Rutgers, B. Exploring the role of microRNAs in brentuximab vedotin resistance in classic Hodgkin lymphoma using a CRISPR knockout screen, Functional microRNA screens in classic Hodgkin lymphoma: from surface marker regulation to brentuximab vedotin resistance, 2024, 135."},{"key":"10.1016\/j.prp.2025.156145_bib38","doi-asserted-by":"crossref","first-page":"1309175","DOI":"10.3389\/fgene.2024.1309175","article-title":"Engineering CRISPR\/Cas9 therapeutics for cancer precision medicine","volume":"15","author":"Sharma","year":"2024","journal-title":"Front. Genet."},{"key":"10.1016\/j.prp.2025.156145_bib39","first-page":"67","article-title":"Screening of lymphoma radiotherapy-resistant genes with CRISPR activation library","author":"Luo","year":"2023","journal-title":"Pharm. Pers. Med."},{"key":"10.1016\/j.prp.2025.156145_bib40","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/bloodadvances.2022008966","article-title":"Applying CRISPR-Cas9 screens to dissect hematological malignancies","volume":"7","author":"Iyer","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.prp.2025.156145_bib41","series-title":"Epigenetic Regulators of Non-Hodgkin Lymphoma and CRISPR-Cas9 Gene Therapy for Immune-Mediated Disorders","author":"Elliott","year":"2024"},{"key":"10.1016\/j.prp.2025.156145_bib42","unstructured":"Issa, I.I. Genetic determinants of drug response in diffuse large B-cell lymphoma, 2024."},{"key":"10.1016\/j.prp.2025.156145_bib43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2024.03.012","article-title":"mtDNA regulates cGAS-STING signaling pathway in adenomyosis","volume":"216","author":"Wang","year":"2024","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.prp.2025.156145_bib44","first-page":"2454","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma, Blood","volume":"131","author":"Tiacci","year":"2018","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2025.156145_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110525","article-title":"NF-\u03baB pathway activation during endothelial-to-mesenchymal transition in a rat model of doxorubicin-induced cardiotoxicity","volume":"130","author":"Xu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2025.156145_bib46","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.7150\/ijbs.67892","article-title":"Advances in multi-omics study of prognostic biomarkers of diffuse large B-cell lymphoma","volume":"18","author":"Liang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.prp.2025.156145_bib47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3892\/or.2023.8621","article-title":"Single\u2011cell multi\u2011omics advances in lymphoma research (Review)","volume":"50","author":"Jin","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2025.156145_bib48","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.prp.2016.11.001","article-title":"Mutation analysis of tumor necrosis factor alpha-induced protein 3 gene in Hodgkin lymphoma","volume":"213","author":"Etzel","year":"2017","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156145_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153781","article-title":"Expression and prognostic analysis of STAT6(YE361) in Hodgkin lymphoma","volume":"231","author":"Yang","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156145_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2021.06.008","article-title":"Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy","volume":"517","author":"Wang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2025.156145_bib51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.omto.2022.10.011","article-title":"Gene-edited and CAR-NK cells: opportunities and challenges with engineering of NK cells for immunotherapy","volume":"27","author":"Wu","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.prp.2025.156145_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.804401","article-title":"Identification of a novel mutation in TNFAIP3 in a family with poly-autoimmunity","volume":"13","author":"Rossi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2025.156145_bib53","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00277-022-04949-x","article-title":"Circulating tumor DNA in Hodgkin lymphoma","volume":"101","author":"Maco","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.prp.2025.156145_bib54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/PAS.0000000000001956","article-title":"Targeted mutational profiling reveals clonal relationships in metachronous occurrence of classic Hodgkin and Mediastinal large B-cell lymphomas","volume":"47","author":"Singh","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156145_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-020-0720-8","article-title":"Immunomodulators in lymphoma","volume":"21","author":"Anagnostou","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.prp.2025.156145_bib57","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/bjh.14449","article-title":"Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma","volume":"180","author":"Kalac","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.prp.2025.156145_bib58","first-page":"2515","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.prp.2025.156145_bib59","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3390\/cancers14133222","article-title":"Novel approaches in molecular characterization of classical Hodgkin Lymphoma","volume":"14","author":"van Bladel","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib60","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.prp.2025.156145_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl3975","article-title":"A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors","volume":"10","author":"Schulthei\u00df","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.prp.2025.156145_bib62","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12935-021-02191-5","article-title":"TNFAIP3 mutation may be associated with favorable overall survival for patients with T-cell lymphoma","volume":"21","author":"Chen","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2025.156145_bib63","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1182\/blood-2023-189886","article-title":"Cooperative somatic alterations in XPO1 and TNFAIP3 (A20) promote immune modulation and tissue infiltration in primary mediastinal B cell lymphoma","volume":"142","author":"Whipp","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156145_bib64","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/biomedicines9091278","article-title":"NF-\u03baB-Dependent and-independent (moonlighting) I\u03baB\u03b1 functions in differentiation and cancer","volume":"9","author":"Espinosa","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.prp.2025.156145_bib65","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s43046-022-00154-z","article-title":"Genomic landscape of mature B-cell non-Hodgkin lymphomas\u2014an appraisal from lymphomagenesis to drug resistance","volume":"34","author":"Panda","year":"2022","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2025.156145_bib66","series-title":"The Major Histocompatibility Complex Class I in the Pathogenesis of B-Cell Lymphomas","author":"Gomez","year":"2023"},{"key":"10.1016\/j.prp.2025.156145_bib67","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2025.156145_bib68","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104504118","article-title":"Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma","volume":"118","author":"Fangazio","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2025.156145_bib69","doi-asserted-by":"crossref","first-page":"1432869","DOI":"10.3389\/fonc.2024.1432869","article-title":"Evaluation of a three-gene methylation model for correlating lymph node metastasis in postoperative early gastric cancer adjacent samples","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib70","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1038\/s41598-021-84465-6","article-title":"B2M overexpression correlates with malignancy and immune signatures in human gliomas","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2025.156145_bib71","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.3390\/ijms25136844","article-title":"The role of the JAK\u2013STAT pathway in childhood B-cell acute lymphoblastic leukemia","volume":"25","author":"Zi\u0119tara","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156145_bib72","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12185-023-03692-x","article-title":"STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment","volume":"119","author":"Benoit","year":"2024","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.prp.2025.156145_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153477","article-title":"STAT6: a review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology","volume":"223","author":"Karpathiou","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156145_bib74","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/PAS.0000000000002062","article-title":"Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg\u2013like Cells","volume":"47","author":"Satou","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156145_bib75","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CCO.0000000000000396","article-title":"The genetics of Hodgkin lymphoma: an overview and clinical implications","volume":"29","author":"Borchmann","year":"2017","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib76","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/leu.2015.328","article-title":"Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma","volume":"30","author":"Hartmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2025.156145_bib77","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2002-05-1592","article-title":"Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma","volume":"101","author":"Wlodarska","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156145_bib78","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156145_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.16914","article-title":"Epigenetic targeting in lymphoma","volume":"192","author":"Booth","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.prp.2025.156145_bib80","doi-asserted-by":"crossref","first-page":"602","DOI":"10.52586\/4970","article-title":"Methylation alterations and advance of treatment in lymphoma","volume":"26","author":"Liu","year":"2021","journal-title":"Front. Biosci. Landmark"},{"key":"10.1016\/j.prp.2025.156145_bib81","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/hemato3010015","article-title":"Epigenetic Modifications in Lymphoma and Their Role in the Classification of Lymphomas","volume":"3","author":"Harrop","year":"2022","journal-title":"Hemato"},{"key":"10.1016\/j.prp.2025.156145_bib82","article-title":"The status and prospects of epigenetics in the treatment of lymphoma","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100782","article-title":"Diagnosis and treatment of lymphomas in the era of epigenetics","volume":"48","author":"Chebly","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.prp.2025.156145_bib84","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res."},{"key":"10.1016\/j.prp.2025.156145_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101830","article-title":"Advances in Hodgkin Lymphoma treatment: from molecular biology to clinical practice","volume":"16","author":"Benevolo Savelli","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib86","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cbf.3463","article-title":"Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape","volume":"38","author":"Liu","year":"2020","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.prp.2025.156145_bib87","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/1568009620666210106122750","article-title":"Epigenetic mechanisms of therapy resistance in diffuse large B cell lymphoma (DLBCL)","volume":"21","author":"Isshiki","year":"2021","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.prp.2025.156145_bib88","unstructured":"Hosta\u0161, O. Epigenetic Dysregulation through Histone Modifications in Lymphoma, 2023."},{"key":"10.1016\/j.prp.2025.156145_bib89","doi-asserted-by":"crossref","first-page":"1420920","DOI":"10.3389\/fonc.2024.1420920","article-title":"Immune checkpoint inhibitors targeting PD-1\/PD-L1 in the treatment of human lymphomas","volume":"14","author":"Ribatti","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib90","doi-asserted-by":"crossref","first-page":"9350272","DOI":"10.1155\/2020\/9350272","article-title":"Current clinical applications and future perspectives of immune checkpoint inhibitors in non-Hodgkin Lymphoma","volume":"2020","author":"Apostolidis","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.prp.2025.156145_bib91","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.3390\/ijms25126447","article-title":"Programmed death ligand 1 (PD-L1) expression in lymphomas: state of the art","volume":"25","author":"Zanelli","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156145_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100832","article-title":"Immunity reloaded: deconstruction of the PD-1 axis in B cell lymphomas","volume":"50","author":"Bednarska","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.prp.2025.156145_bib93","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2025.156145_bib94","doi-asserted-by":"crossref","first-page":"10740","DOI":"10.1038\/s41467-024-54512-7","article-title":"Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma","volume":"15","author":"Paczkowska","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2025.156145_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004114","article-title":"Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL","volume":"10","author":"Zhang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2025.156145_bib96","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.3390\/cancers13225833","article-title":"HLA expression in relation to HLA type in classic Hodgkin lymphoma patients","volume":"13","author":"Tan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib97","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.HS9.0000890724.84249.84","article-title":"P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma","volume":"6","author":"Grund","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.prp.2025.156145_bib98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/15513815.2020.1764680","article-title":"PD-L1 and PD-L2 mutations in pediatric Hodgkin Lymphoma: do they have any prognostic significance?","volume":"41","author":"G\u00fcl","year":"2022","journal-title":"Fetal Pediatr. Pathol."},{"key":"10.1016\/j.prp.2025.156145_bib99","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer\u2014mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2024.112389","article-title":"Kaempferol: paving the path for advanced treatments in aging-related diseases","volume":"188","author":"Hussain","year":"2024","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.prp.2025.156145_bib101","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2020","journal-title":"Medicina"},{"key":"10.1016\/j.prp.2025.156145_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154773","article-title":"Probing the links: long non-coding RNAs and NF-\u03baB signalling in atherosclerosis","volume":"249","author":"Hussain","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156145_bib103","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3390\/diagnostics12061507","article-title":"Hodgkin Lymphoma: biology and differential diagnostic problem","volume":"12","author":"Takahara","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.prp.2025.156145_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.5567","article-title":"Lymphocyte predominant Hodgkin lymphoma, antigen-driven after all?","volume":"253","author":"Poppema","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2025.156145_bib105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3324\/haematol.2018.203224","article-title":"JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell\/histiocyte-rich large B-cell lymphoma","volume":"104","author":"Schuhmacher","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.prp.2025.156145_bib106","first-page":"3443","article-title":"Histopathology and Immunohistochemical profile of mediastinal lymphoma in Dr. Soetomo General Hospital","volume":"6","author":"Kusumastuti","year":"2022","journal-title":"Hospital"},{"key":"10.1016\/j.prp.2025.156145_bib107","article-title":"Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Review of Current Literature and Case Discussion","volume":"10","author":"Sidda","year":"2022","journal-title":"J. Invest. Med. High. Impact Case Rep."},{"key":"10.1016\/j.prp.2025.156145_bib108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2021.06.028","article-title":"PET\/CT metabolic patterns in systemic immune activation: a new perspective on the assessment of immunotherapy response and efficacy","volume":"520","author":"Jin","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2025.156145_bib109","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/08880018.2015.1071903","article-title":"Prognostic biomarkers for Hodgkin lymphoma","volume":"32","author":"Staege","year":"2015","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib110","doi-asserted-by":"crossref","DOI":"10.5644\/ama2006-124.329","article-title":"Classic Hodgkin Lymphoma--old disease, new directions: an update on pathology, molecular features and biological prognostic markers","volume":"50","author":"Perry","year":"2021","journal-title":"Acta Med. Acad."},{"key":"10.1016\/j.prp.2025.156145_bib111","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1038\/s41375-021-01314-1","article-title":"Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP","volume":"35","author":"Jachimowicz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2025.156145_bib112","doi-asserted-by":"crossref","first-page":"1068662","DOI":"10.3389\/fimmu.2023.1068662","article-title":"Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer\/T-cell lymphoma","volume":"14","author":"Yap","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2025.156145_bib113","series-title":"Precision Molecular Pathology of Aggressive B-Cell Lymphomas","first-page":"83","article-title":"Next-Generation Sequencing-Based Methods for the Detection of B-Cell Clonality","author":"Miller","year":"2024"},{"key":"10.1016\/j.prp.2025.156145_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104503","article-title":"Minimal residual disease testing for classical Hodgkin Lymphoma: a comprehensive review","author":"Arai","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.prp.2025.156145_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bea.2023.100092","article-title":"Medical diagnostic value of digital PCR (dPCR): a systematic review","volume":"6","author":"Nazir","year":"2023","journal-title":"Biomed. Eng. Adv."},{"key":"10.1016\/j.prp.2025.156145_bib116","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5858\/arpa.2020-0795-OA","article-title":"Role of flow cytometric immunophenotyping for classic Hodgkin lymphoma in small biopsy and cytology specimens","volume":"146","author":"Chan","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2025.156145_bib117","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pathol.2022.07.005","article-title":"A new approach to the study of Hodgkin lymphoma by flow cytometry","volume":"55","author":"Flores","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.prp.2025.156145_bib118","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cyt.13255","article-title":"Liquid biopsy: a promising tool for driving strategies and predicting failures in patients with classic Hodgkin lymphoma","volume":"35","author":"Pepe","year":"2024","journal-title":"Cytopathology"},{"key":"10.1016\/j.prp.2025.156145_bib119","first-page":"45","article-title":"Chapter Two - PCR-Based Detection Methods for Single-Nucleotide Polymorphism or Mutation: Real-Time PCR and Its Substantial Contribution Toward Technological Refinement","volume":"80","author":"Matsuda","year":"2017"},{"key":"10.1016\/j.prp.2025.156145_bib120","first-page":"1","article-title":"Hodgkin lymphoma: the role of EBV plasma viral load testing in an HIV-endemic setting","volume":"25","author":"Opie","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.prp.2025.156145_bib121","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/ph14030207","article-title":"Cell-Free DNA for the management of classical Hodgkin Lymphoma","volume":"14","author":"Camus","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.prp.2025.156145_bib122","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/hon.2956","article-title":"Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma","volume":"40","author":"Cao","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib123","doi-asserted-by":"crossref","first-page":"9911","DOI":"10.3390\/ijms23179911","article-title":"Quantitative plasma proteomics to identify candidate biomarkers of relapse in pediatric\/adolescent Hodgkin lymphoma","volume":"23","author":"Repetto","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156145_bib124","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.2024024487","article-title":"Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma","volume":"144","author":"Nie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156145_bib125","doi-asserted-by":"crossref","unstructured":"Alabiad, M.A.; Balata, R.; Asmaa, A.; Metwally, E.A.; Shalaby, A.; Samy, W.; Yehia, A.M.M.; Said, W.M.; Khairy, D.A.; Yahia, A.I.O. EBV promotes tumorigenicity and worsens the prognosis of Hodgkin lymphoma through the expression of survival enhancing proteins by activating the JAK\/STAT and NF-kB signaling pathways.(A comparative study between EBV positive and negative Hodgkin lymphoma), 2022.","DOI":"10.21203\/rs.3.rs-1857436\/v1"},{"key":"10.1016\/j.prp.2025.156145_bib126","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2329130","article-title":"Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma","volume":"56","author":"Shi","year":"2024","journal-title":"Ann. Med."},{"key":"10.1016\/j.prp.2025.156145_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100061","article-title":"Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis","volume":"2","author":"Fonseca","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.prp.2025.156145_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12020409","article-title":"Update on molecular diagnosis in extranodal NK\/T-cell lymphoma and its role in the era of personalized medicine","volume":"12","author":"Sun","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.prp.2025.156145_bib129","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/ijc.34281","article-title":"CD25: a potential tumor therapeutic target","volume":"152","author":"Peng","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2025.156145_bib130","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood-2021-149675","article-title":"Ruxolitinib plus Nivolumab in patients with R\/R Hodgkin Lymphoma after failure of check-point inhibitors: preliminary report on safety and efficacy","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156145_bib131","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/cancers13040884","article-title":"Biology and clinical applicability of plasma thymus and activation-regulated chemokine (TARC) in classical Hodgkin Lymphoma","volume":"13","author":"Zijtregtop","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib132","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13148-023-01452-6","article-title":"Clinical advances in epigenetic therapies for lymphoma","volume":"15","author":"Rosenthal","year":"2023","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.prp.2025.156145_bib133","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/cancers14061469","article-title":"Tumor immune microenvironment in lymphoma: focus on epigenetics","volume":"14","author":"Garc\u00eda-Dom\u00ednguez","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib134","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.599561","article-title":"Biomodulatory treatment regimen, MEPED, rescues relapsed and refractory classic Hodgkin\u2019s disease","volume":"12","author":"L\u00fcke","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.prp.2025.156145_bib135","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.3390\/cancers15184509","article-title":"Optimizing treatment for relapsed\/refractory classic Hodgkin Lymphoma in the era of immunotherapy","volume":"15","author":"Randall","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib136","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3390\/ijms25052457","article-title":"Pathogenic variants associated with epigenetic control and the NOTCH pathway are frequent in classic Hodgkin Lymphoma","volume":"25","author":"Santisteban-Espejo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156145_bib137","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41375-022-01774-z","article-title":"Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma","volume":"37","author":"Wei","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2025.156145_bib138","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000971","article-title":"CAR-T cell therapy for classical Hodgkin Lymphoma","volume":"7","author":"Katsin","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.prp.2025.156145_bib139","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/jpm12020197","article-title":"The emerging role of CAR T cell therapy in relapsed\/refractory Hodgkin Lymphoma","volume":"12","author":"Meier","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.prp.2025.156145_bib140","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","article-title":"Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research","volume":"36","author":"Lauer","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2025.156145_bib141","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12032-022-01711-1","article-title":"Artificial intelligence and machine learning in precision and genomic medicine","volume":"39","author":"Quazi","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib142","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and Reed Sternberg cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.prp.2025.156145_bib143","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.3390\/cancers13153744","article-title":"Development and implementation of proton therapy for Hodgkin Lymphoma: challenges and perspectives","volume":"13","author":"Loap","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156145_bib144","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41436-018-0090-9","article-title":"Ethical, social, and cultural issues related to clinical genetic testing and counseling in low-and middle-income countries: a systematic review","volume":"23","author":"Zhong","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.prp.2025.156145_bib145","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/EDBK_350652","article-title":"Artificial intelligence in oncology: current capabilities, future opportunities, and ethical considerations","volume":"42","author":"Shreve","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.prp.2025.156145_bib146","first-page":"777","article-title":"CRISPR\u2013Cas9: a history of its discovery and ethical considerations of its use in genome editing","volume":"87","author":"Gostimskaya","year":"2022","journal-title":"Biochemistry)"},{"key":"10.1016\/j.prp.2025.156145_bib147","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially resolved tumor microenvironment predicts treatment outcomes in relapsed\/refractory Hodgkin lymphoma","volume":"42","author":"Aoki","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib148","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin Lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib149","doi-asserted-by":"crossref","first-page":"34","DOI":"10.33696\/haematology.5.059","article-title":"Decoding Hodgkin's Lymphoma: advances in biology, diagnostics, and therapeutic strategies","volume":"5","author":"Addissouky","year":"2024","journal-title":"J. Clin. Haematol."},{"key":"10.1016\/j.prp.2025.156145_bib150","article-title":"Artificial intelligence-driven precision medicine: multi-omics and spatial multi-omics approaches in diffuse large B-cell Lymphoma (DLBCL)","volume":"29","author":"Shao","year":"2024","journal-title":"FBL"},{"key":"10.1016\/j.prp.2025.156145_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1170","article-title":"1941P Preliminary efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: a phase II trial","volume":"34","author":"Hu","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2025.156145_bib152","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1038\/s41467-023-40186-0","article-title":"Ezh2 emerges as an epigenetic checkpoint regulator during monocyte differentiation limiting cardiac dysfunction post-MI","volume":"14","author":"Rondeaux","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825003383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825003383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T14:26:09Z","timestamp":1755095169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825003383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":152,"alternative-id":["S0344033825003383"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156145","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular carcinogenesis in Hodgkin lymphoma: Interplay between B lymphocyte mutations and NF-\u03baB pathway dysregulation","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"156145"}}